At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 46 enrolled

Drug / intervention

Eslicarbazepine +1 moredrug

Likely dose

Eslicarbazepine 800mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02912364

NCT02912364Phase 4Completed

Compare CT.gov

Double-Blind, Randomized, Two Period Crossover Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

Stanford University·interventional·Posted Sep 23, 2016·Updated Jun 4, 2019

In Brief

A Phase 4 clinical trial evaluating Eslicarbazepine and Carbamazepine for Epilepsy. Completed, enrolled 46 participants across 1 site.

Detailed Summary

Double-blind, randomized, two period crossover comparison of the cognitive and behavioral effects of Eslicarbazepine acetate and Carbamazepine in healthy volunteers.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsEpilepsy

CountriesUnited States

CollaboratorsSumitomo Pharma America, Inc.

Timeline

Phase 4CompletedFinished

2017201820192020202120222023202420252026

Enrollment StartJul 2016

First PostedSep 2016

Primary CompletionApr 2018

TodayJul 2026

First PostedSep 23, 2016

Enrollment StartJul 1, 2016

Primary CompletionApr 20, 2018

TodayJul 2, 2026

Enrollment to primary: 1.8 yearsPosted 9.8 years ago

Interventions

Eslicarbazepinedrug

Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.

Carbamazepinedrug

Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.